The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Nanoparticle-based targeted drug delivery
Open accessAbstract
Nanotechnology could be defined as the technology that has allowed for the control, manipulation, study, and manufacture of structures and devices in the “nanometer” size range. These nano-sized objects, e.g., “nanoparticles”, take on novel properties and functions that differ markedly from those seen from items made of identical materials. The small size, customized surface, improved solubility, and multi-functionality of nanoparticles will continue to open many doors and create new biomedical applications. Indeed, the novel properties of nanoparticles offer the ability to interact with complex cellular functions in new ways. This rapidly growing field requires cross-disciplinary research and provides opportunities to design and develop multifunctional devices that can target, diagnose, and treat devastating diseases such as cancer. This article presents an overview of nanotechnology for the biologist and discusses the attributes of our novel XPclad© nanoparticle formulation that has shown efficacy in treating solid tumors, for single dose vaccination, and oral delivery of therapeutic proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Maeda, H. (2001) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(00)00013-3 · Cited by 2,495
Encyclopedia of Pharmaceutical Technology
Swarbrick, J. (2013) · CRC Press eBooks · doi:10.1201/b19309 · Cited by 1,794
Encyclopedia of pharmaceutical technology
(2003) · Choice Reviews Online · doi:10.5860/choice.40-6157 · Cited by 1,743
Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., & Maitra, A. (2007) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-5-3 · Cited by 1,090
Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs
Lu, J., Liong, M., Zink, J. I., & Tamanoi, F. (2007) · Small · doi:10.1002/smll.200700005 · Cited by 1,012
Govender, T. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(98)00116-3 · Cited by 1,008
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
Desai, M. P., Labhasetwar, V., Amidon, G. L., & Levy, R. J. (1996) · Pharmaceutical Research · doi:10.1023/a:1016085108889 · Cited by 941
The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858
Pitt, G. G., Gratzl, M. M., Kimmel, G. L., Surles, J., & Sohindler, A. (1981) · Biomaterials · doi:10.1016/0142-9612(81)90060-0 · Cited by 857
Calvo, P., Remuñan-López, C., Vila-Jato, J. L., & Alonso, M. J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012128907225 · Cited by 817
Lee, C. C., Gillies, E. R., Fox, M. E., Guillaudeu, S. J., Fréchet, J. M. J., Dy, E. E., & Szoka, F. C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607705103 · Cited by 650
Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier
Lockman, P. R., Mumper, R. J., Khan, M. A., & Allen, D. D. (2002) · Drug Development and Industrial Pharmacy · doi:10.1081/ddc-120001481 · Cited by 592 · cited 1×
“Nanoparticles also can be formulated to deliver drugs across several biological barriers (Fisher and Ho, 2002; Lockman et al., 2002).”
BackgroundFunctionalized micellar systems for cancer targeted drug delivery
Sutton, D., Nasongkla, N., Blanco, E., & Gao, J. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9223-y · Cited by 557
Nanocapsule Technology: A Review
Couvreur, P., Barratt, G., Fattal, E., & Vauthier, C. (2002) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v19.i2.10 · Cited by 555
Panyam, J., Dali, M. M., Sahoo, S. K., Ma, W., Chakravarthi, S. S., Amidon, G. L., Levy, R. J., & Labhasetwar, V. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(03)00328-6 · Cited by 529
Characterization of nanoparticle uptake by endothelial cells
Davda, J., & Labhasetwar, V. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00923-1 · Cited by 524
Avgoustakis, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00530-2 · Cited by 503
Colloidal Drug Delivery Systems
Kreuter, J. (2014) · CRC Press eBooks · doi:10.1201/9781498710565 · Cited by 469
Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469
Synthesis and RGD peptide modification of a new biodegradable copolymer: poly(lactic acid-co-lysine)
Barrera, D. A., Zylstra, E., Lansbury, P. T., & Langer, R. (1993) · Journal of the American Chemical Society · doi:10.1021/ja00076a077 · Cited by 456
Tumor Targeting with Antibody-Functionalized, Radiolabeled Carbon Nanotubes
McDevitt, M. R., Chattopadhyay, D., Kappel, B. J., Jaggi, J. S., Schiffman, S. R., Antczak, C., Njardarson, J. T., Brentjens, R., & Scheinberg, D. A. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.039131 · Cited by 452
Dunne, M., Corrigan, O. I., & Ramtoola, Z. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00040-5 · Cited by 444
Drug transport to brain with targeted nanoparticles
Olivier, J.-C. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.108 · Cited by 444
Redhead, H. M., Davis, S. S., & Illum, L. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00367-9 · Cited by 419
Colloidal drug delivery systems
Duncan-Hewitt, W. C. (1995) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/0927-7765(95)90010-1 · Cited by 419
In vitro uptake of polystyrene microspheres: effect of particle size, cell line and cell density
Zauner, W., Farrow, N. A., & Haines, A. M. R. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00358-8 · Cited by 411
Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410
Biodegradable Nanoparticles for Targeted Drug Delivery in Treatment of Inflammatory Bowel Disease
Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Maincent, P., Kawashima, Y., & Lehr, C.-M. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29290-9 · Cited by 403
The intracellular degradation of poly(ε‐caprolactone)
Woodward, S. C., Brewer, P. S., Moatamed, F., Schindler, A., & Pitt, C. G. (1985) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820190408 · Cited by 380
Controlled drug delivery with nanoparticles : current possibilities and future trends
Couvreur, P., Dubernet, C., & Puisieux, F. (1995) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 356
Multi-functional polymeric nanoparticles for tumour-targeted drug delivery
van Vlerken, L. E., & Amiji, M. M. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.2.205 · Cited by 352
Tada, H., Higuchi, H., Wanatabe, T. M., & Ohuchi, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1185 · Cited by 352
Ahmed, F., Pakunlu, R. I., Srinivas, G., Brannan, A., Bates, F., Klein, M. L., Minko, T., & Discher, D. E. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050103u · Cited by 330
Panyam, J., Williams, D., Dash, A., Leslie‐Pelecky, D., & Labhasetwar, V. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20094 · Cited by 320
Panyam, J., Sahoo, S. K., Prabha, S., Bargar, T., & Labhasetwar, V. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00295-3 · Cited by 308
MacDiarmid, J. A., Mugridge, N. B., Weiss, J. C., Phillips, L., Burn, A. L., Paulin, R. P., Haasdyk, J. E., Dickson, K.-A., Brahmbhatt, V. N., Pattison, S. T., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.03.012 · Cited by 307
Pharmacokinetics and distribution of a biodegradable drug-carrier
Grislain, L., Couvreur, P., Lenaerts, V., Roland, M., Deprez-Decampeneere, D., & Speiser, P. (1983) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(83)90166-7 · Cited by 305
Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles
Vauthier, C. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.005 · Cited by 283
Therapeutic applications of colloidal drug carriers
Barratt, G. M. (2000) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(00)00255-8 · Cited by 282
Peracchia, M. T., Gref, R., Minamitake, Y., Domb, A., Lotan, N., & Langer, R. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(96)01597-0 · Cited by 266
Magenheim, B., Levy, M. Y., & Benita, S. (1993) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(93)90015-8 · Cited by 250
Self-assembled particles of an elastin-like polymer as vehicles for controlled drug release
Herrero-Vanrell, R., Rincón, A. C., Alonso, M., Reboto, V., Molina-Martinez, I. T., & Rodríguez-Cabello, J. C. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.10.001 · Cited by 241
Defining the drug incorporation properties of PLA–PEG nanoparticles
Govender, T. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00375-6 · Cited by 225
Müller, R., Maaben, S., Weyhers, H., & Mehnert, W. (1996) · Journal of Drug Targeting · doi:10.3109/10611869609015973 · Cited by 222
Ge, H., Hu, Y., Jiang, X., Cheng, D., Yuan, Y., Bi, H., & Yang, C. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10143 · Cited by 199
Pegnology: a review of PEG-ylated systems.
Bhadra, D., Bhadra, S., Jain, P., & Jain, N. K. (2002) · PubMed · Cited by 183
Guzman, L. A., Labhasetwar, V., Song, C., Jang, Y., Lincoff, A. M., Levy, R., & Topol, E. J. (1996) · Circulation · doi:10.1161/01.cir.94.6.1441 · Cited by 177
Chitosan-dextran Sulfate Nanoparticles for Delivery of an Anti-angiogenesis Peptide
Chen, Y., Mohanraj, V. J., & Parkin, J. E. (2003) · International Journal of Peptide Research and Therapeutics · doi:10.1007/bf02442596 · Cited by 166
Programmed drug delivery: nanosystems for tumor targeting
Wagner, E. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.5.587 · Cited by 157
Fresta, M., Puglisi, G., Giammona, G., Cavallaro, G., Micali, N. L., & Furneri, P. M. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840721 · Cited by 152
Sahoo, S. K., Sawa, T., Fang, J. Q., Tanaka, S., Miyamoto, Y., Akaike, T., & Maeda, H. (2002) · Bioconjugate Chemistry · doi:10.1021/bc020010k · Cited by 138
Kroll, R. A., Pagel, M. A., Muldoon, L. L., Muldoon, L. L., Roman-Goldstein, S., Fiamengo, S. A., Neuwelt, E. A., Neuwelt, E. A., & Neuwelt, E. A. (1998) · Neurosurgery · doi:10.1097/00006123-199810000-00090 · Cited by 118
Potential New Methods for Antiepileptic Drug Delivery
Fisher, R. S., & Ho, J. (2002) · CNS Drugs · doi:10.2165/00023210-200216090-00001 · Cited by 103
Use of nanoparticles for drug delivery in glioblastoma multiforme
Jain, K. K. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.4.363 · Cited by 99
Beletsi, A., Leontiadis, L., Klepetsanis, P. G., Ithakissios, D. S., & Avgoustakis, K. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00058-7 · Cited by 96
Antibiological barrier nanovector technology for cancer applications
Sakamoto, J. H., Annapragada, A., Decuzzi, P., & Mauro Ferrari, B. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.359 · Cited by 78
Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumors
Peng, W., Anderson, D. G., Bao, Y., Padera, R. F., Langer, R., & Sawicki, J. A. (2007) · The Prostate · doi:10.1002/pros.20576 · Cited by 59
CHEN, Y., MCCULLOCH, R., & GRAY, B. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90250-x · Cited by 54
Boyd, B. J. (2005) · Cited by 14
Cited by
DLS and zeta potential – What they are and what they are not?
Bhattacharjee, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.017 · Cited by 4,702
Metal nanoparticles: understanding the mechanisms behind antibacterial activity
Slavin, Y. N., Asnis, J., Häfeli, U. O., & Bach, H. (2017) · Journal of Nanobiotechnology · doi:10.1186/s12951-017-0308-z · Cited by 2,571
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
A Review on Nanofluids: Preparation, Stability Mechanisms, and Applications
Yu, W., & Xie, H. (2012) · Journal of Nanomaterials · doi:10.1155/2012/435873 · Cited by 1,770
Polymer-based nanocapsules for drug delivery
Mora-Huertas, C. E., Fessi, H., & Elaissari, A. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.10.018 · Cited by 1,742
Metadata
- Authors
- Singh, R., & Lillard, J. W.
- Venue
- Experimental and Molecular Pathology
- Publisher
- Elsevier BV
- Published
- 2009-06
- Volume
- 86
- Issue
- 3
- Pages
- 215-223
- ISSN
- 0014-4800 (ISSN-L)
- OpenAlex
- W1996697333
- Cited by
- 2,734
- References
- 62
- FWCI
- 24.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.